An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns, per Dr. Lydia Scarfò.
Dr. Lydia Scarfò
Advertisement
Articles by Dr. Lydia Scarfò
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Orphan Drug Designation to Utidelone in Pancreatic Cancer
2
What Is the Difference Between a Clinical Trial and a Real-World Study?
3
Guiding the Diagnosis and Treatment of Cancer During Pregnancy
4
Exercise Helps Me Feel in Control While Living With Metastatic Breast Cancer
5
